Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 2:10 PM ET

Pharmaceuticals

Company Overview of Kiadis Pharma N.V.

Company Overview

Kiadis Pharma N.V. researches, develops, and commercializes cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products provide for Allodepleted T-cell ImmunotheRapeutics (ATIR). The company offers ATIR101 that addresses the risks and limitations of current hematopoietic stem cell transplantation treatments in blood cancers. The company also develops ATIR201 for inherited blood disorders with an initial focus on thalassemia. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam-Duivendrecht, the Netherlands.

Entrada 200

kant. 231

Amsterdam-Duivendrecht,  1114 AA

Netherlands

Founded in 1997

23 Employees

Phone:

31 20 314 0250

Fax:

31 20 314 0251

Key Executives for Kiadis Pharma N.V.

Chief Executive Officer
Chief Financial Officer
Chief Medical Officer and Senior Vice President
General Counsel and Corporate Secretary
Compensation as of Fiscal Year 2015.

Kiadis Pharma N.V. Key Developments

Kiadis Pharma N.V. Auditor Raises 'Going Concern' Doubt

Kiadis Pharma N.V. filed its Annual on Jun 17, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Kiadis Pharma Seeks Acqusiitions

Kiadis Pharma B.V. will use the proceeds of the IPO in the amount of €35.94million to finance potential opportunities to broaden and diversify the research and development portfolio (e.g. through in-licensing or the acquisition of programs and companies with synergistic or complementary technologies, products and/or product candidates.)

Kiadis Pharma To File IPO

Kiadis Pharma B.V. is planning to raise funds for research through the listing of its shares on the Amsterdam and Brussels stock exchanges. It intends to use the net proceeds to support further clinical development of ATIR101 and ATIR201, production process optimization and automation, diversify the R&D portfolio, and remaining proceeds for working capital and general corporate purposes.

Similar Private Companies By Industry

Company Name Region
Fresenius Hemocare B.V. Europe
Isotron Nederland B.V. Europe
Synthon Holding B.V. Europe
Diosynth Holding B.V. Europe
Sanofi-aventis Netherlands B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kiadis Pharma N.V., please visit www.kiadis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.